$0.55
0.00%
Nasdaq, Thu, Feb 27 2025
ISIN
US56854Q1013
Symbol
MRNS
Sector
Industry

Marinus Pharmaceuticals Inc Stock price

$0.55
+0.01 1.35% 1M
-0.92 62.59% 6M
+0.01 2.78% YTD
-9.45 94.50% 1Y
-7.27 92.97% 3Y
-9.69 94.63% 5Y
-45.29 98.80% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.00 0.00%
ISIN
US56854Q1013
Symbol
MRNS
Sector
Industry

Key metrics

Market capitalization $29.63m
Enterprise Value $82.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.63
P/S ratio (TTM) P/S ratio 0.94
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1.63%
Revenue (TTM) Revenue $31.47m
EBIT (operating result TTM) EBIT $-122.62m
Free Cash Flow (TTM) Free Cash Flow $-115.93m
Cash position $42.18m
EPS (TTM) EPS $-2.47
P/E forward negative
P/S forward 0.83
EV/Sales forward 2.30
Short interest 10.32%
Show more

Is Marinus Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Marinus Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Marinus Pharmaceuticals Inc forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Marinus Pharmaceuticals Inc forecast:

Hold
100%

Financial data from Marinus Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
31 31
2% 2%
100%
- Direct Costs 3.62 3.62
77% 77%
12%
28 28
4% 4%
88%
- Selling and Administrative Expenses 63 63
5% 5%
199%
- Research and Development Expense 87 87
7% 7%
277%
-122 -122
2% 2%
-388%
- Depreciation and Amortization 0.53 0.53
25% 25%
2%
EBIT (Operating Income) EBIT -123 -123
2% 2%
-390%
Net Profit -140 -140
5% 5%
-446%

In millions USD.

Don't miss a Thing! We will send you all news about Marinus Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Marinus Pharmaceuticals Inc Stock News

Neutral
Business Wire
about 2 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marinus Pharmaceuticals, Inc. (NasdaqGM: MRNS) to Immedica Pharma AB. Under the terms of the proposed transaction, shareholders of Marinus will receive $0.55 in cash for each share of Marinus that they own. KSF is...
Neutral
Business Wire
2 months ago
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Marinus (Nasdaq: MRNS) for possible breaches of fiduciary duty and other violations of law in its transaction with the Immedica. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Marin...
Neutral
Business Wire
2 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) to Immedica Pharma AB for $0.55 per share is fair to Marinus shareholders. Halper Sadeh encourages Marinus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0...
More Marinus Pharmaceuticals Inc News

Company Profile

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Head office United States
CEO Anders Edvell
Employees 165
Founded 2003
Website www.marinuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today